Læknablaðið

Årgang

Læknablaðið - dec. 2020, Side 21

Læknablaðið - dec. 2020, Side 21
L ÆK N A BL AÐIÐ 2020/106 579 R A N N S Ó K N doi 10.17992/lbl.2020.12.611 INTRODUCTION: The COVID-19 pandemic has caused public health and economic turmoil across the globe. Severe COVID-19 disease most often presents with pneu- monia and complications in acutely ill patients often stem from the lungs. The as- sociations of lung disease, smoking and e-cigarette use with the incidence and severity of COVID-19 are unclear on a population level. METHODS: Data on 1761 patients from the Icelandic outpatient Landspitali COV- ID-19 Clinic were used. The prevalence of smoking, e-cigarette use and underlying lung diseases was calculated in the cohort, with stratification based on age groups and a clinical classification of symptom severity. It was tested whether these prev- alences differed between age groups and classes of symptom severity. RESULTS: Most patients were in the age group between 35-54 years of age and a large majority had mild symptoms at diagnosis. The prevalence of smoking was 6% with the highest prevalence among 35-54 year olds. The prevalence of e-cig- arette use was 4%. It was most prevalent in the age group between 18-34 years. There was no difference in the prevalence of smoking or e-cigarette use between classes of symptom severity. The prevalence of lung disease was 9%. It was higher among older patients and patients with more severe symptoms. CONCLUSION: The age distribution and prevalence of lung disease and their risk factors are described in the context of COVID-19 incidence and symptom severity in a whole-nation cohort of Icelanders. The cohort is younger and had less severe symptoms than in many previosly published studies of COVID-19. Interestingly, the prevalences of smoking and e-cigarette use were lower than in the Icelandic gen- eral population and they were not associated with symptom severity at diagnosis. To conclude, the results presented here indicate that underlying lung diseases are prevalent among people with severe COVID-19 symptoms but fail to demonstrate an association between cigarette smoking or e-cigarette smoking with COVID-19 severity. E N G L I S H S U M M A R Y Gísli Þór Axelsson1,2 Elías Sæbjörn Eyþórsson2 Hrönn Harðardóttir3 Gunnar Guðmundsson1,3 Sif Hansdóttir3 The impact of lung diseases, smoking and e-cigarette use on the severity of COVID-19 illness at diagnosis 1University of Iceland, Faculty of Medicine 2 Landspitali National University hospital, Department of Internal Medicine 3.Landspitali National University Hospital, Department of Respiratory Medicine Correspondence: Sif Hansdóttir, sifhan@landspitali.is Key words: COVID-19, Lung diseases, Smoking, Electronic cigarettes Sér ly f ja tex t i á b l s . 589

x

Læknablaðið

Direkte link

Hvis du vil linke til denne avis/magasin, skal du bruge disse links:

Link til denne avis/magasin: Læknablaðið
https://timarit.is/publication/986

Link til dette eksemplar:

Link til denne side:

Link til denne artikel:

Venligst ikke link direkte til billeder eller PDfs på Timarit.is, da sådanne webadresser kan ændres uden advarsel. Brug venligst de angivne webadresser for at linke til sitet.